Category: Research Peptides | Reading time: 5 min | For research use only
CJC-1295 and Ipamorelin are two synthetic peptides that act on distinct but complementary nodes of the growth hormone (GH) secretion pathway. Both have been studied in preclinical and clinical research contexts, and they frequently appear together in the scientific literature as a model system for investigating synergistic growth hormone secretagogue activity.
This article provides a research-oriented overview of both compounds, their mechanisms, and the published literature examining their combined and individual activity. All compounds discussed are strictly for laboratory and research use only.
Molecular Profiles
CJC-1295
- Class: Growth hormone releasing hormone (GHRH) analogue
- Full name: Drug Affinity Complex: GHRH(1–29)
- Molecular weight: ~3,367 g/mol (DAC form); ~3,036 g/mol (no DAC / Mod GRF 1-29)
- Sequence: Modified GHRH(1–29) with substitutions at positions 2, 8, 15, and 27
- Half-life: ~6–8 days (DAC form); ~30 minutes (no DAC form)
- Form: Lyophilized powder (research grade)
Ipamorelin
- Class: Growth hormone secretagogue / selective ghrelin receptor agonist (GHSR)
- Full name: Ipamorelin (NNC 26-0161)
- Molecular weight: 711.85 g/mol
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Half-life: ~2 hours
- Form: Lyophilized powder (research grade)
The key structural distinction: CJC-1295 mimics GHRH and acts on GHRH receptors in the pituitary, while Ipamorelin mimics ghrelin and acts on ghrelin receptors (GHSR-1a). This dual-pathway approach is the basis for the research interest in their combined use.
Mechanisms of Action
CJC-1295 — GHRH Receptor Pathway
Natural GHRH is released from the hypothalamus and travels to the anterior pituitary, where it binds GHRH receptors and stimulates GH synthesis and release. CJC-1295 was developed as a stabilized analogue of GHRH(1–29) — the biologically active fragment — with four amino acid substitutions that increase resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, extending its activity window.
The DAC (Drug Affinity Complex) form adds a lysine-maleimide moiety that enables reversible covalent binding to serum albumin, dramatically extending half-life from minutes to approximately six days. This property has made CJC-1295 DAC a research tool for studying sustained GHRH receptor stimulation and its downstream effects on GH pulse amplitude.
Research has examined CJC-1295's effects on:
- Pulsatile GH secretion patterns
- IGF-1 (insulin-like growth factor 1) levels in plasma
- Downstream anabolic signaling pathways in muscle and adipose tissue models
Ipamorelin — Ghrelin Receptor Pathway
Ipamorelin is a pentapeptide ghrelin mimetic developed by Novo Nordisk and published in the literature in 1998. It selectively activates the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor — in the pituitary gland, stimulating GH release through a mechanism independent of the GHRH pathway.
The selectivity profile of Ipamorelin has been a central focus of research. Published studies have reported that Ipamorelin produces GH release with minimal co-stimulation of ACTH (adrenocorticotropic hormone) or cortisol secretion — a selectivity advantage compared to earlier GH secretagogues such as GHRP-2 and GHRP-6 which produced more pronounced cortisol and prolactin responses. This selectivity has made Ipamorelin a preferred research tool for isolating GHSR-mediated GH release from HPA axis activation.
Combined Research Applications
The rationale for studying CJC-1295 and Ipamorelin together derives from their complementary receptor targets:
- CJC-1295 acts on GHRH receptors → amplifies GH pulse amplitude
- Ipamorelin acts on GHSR → triggers GH pulse frequency
Research using both compounds simultaneously has investigated whether dual-pathway stimulation produces additive or synergistic GH release compared to either compound alone. Published clinical data from Teichman et al. (2006) demonstrated that CJC-1295 administration produced dose-dependent increases in mean GH concentrations and IGF-1 levels sustained over multiple days — findings that have been used as a reference point for combination models.
In vitro models using pituitary cell cultures have examined receptor crosstalk between GHRH and GHSR signaling pathways, investigating whether simultaneous activation of both pathways produces cooperative signaling effects at the level of cAMP and intracellular calcium mobilization.
Areas of Active Research
Pituitary function models Research using both peptides has examined pituitary somatotroph response patterns, GH pulse kinetics, and feedback regulation involving somatostatin in animal models.
Body composition research Rodent models examining the downstream effects of sustained GH secretagogue exposure on muscle mass, fat mass, and bone density have used CJC-1295 and Ipamorelin as experimental tools to manipulate GH axis activity.
Aging and GH axis research Age-related decline in GH secretion (somatopause) has motivated research using GH secretagogues as investigative tools in aged animal models, examining whether restoration of GH pulse patterns affects metabolic parameters in aged subjects.
Sleep architecture research GH secretion is closely linked to slow-wave sleep in mammals. Research examining ghrelin receptor agonists including Ipamorelin in sleep architecture models has investigated the relationship between GHSR activation and sleep-stage-specific GH release patterns.
Key Published Research
- Jetté L, et al. (2005). hGRF1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: a potential long-acting GRF analog. Endocrinology, 146(7), 3052–3058.
- Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
- Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.
- Holst B, et al. (2005). Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor. Molecular Pharmacology, 67(6), 1974–1984.
Research Considerations
Researchers working with CJC-1295 should confirm whether their compound is the DAC form or the no-DAC form (also known as Modified GRF 1-29), as these have substantially different half-lives and therefore different experimental implications. The two forms require different experimental designs and dosing interval considerations in animal models.
Ipamorelin's selectivity for GHSR over ACTH/cortisol pathways has been demonstrated in rat models; researchers should verify whether this selectivity profile holds in their specific model system, as species differences in receptor pharmacology can affect outcomes.
View CJC-1295 in our catalog →
All products and information provided by NordBioLab are strictly for scientific research and laboratory use only. Not for human or veterinary consumption. This article does not constitute medical advice.